[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 48 of about 48
1. Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P, Cree IA: The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer; 2004 Nov 23;4:83
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
  • METHODS: In this study we have used a standardised ATP-based tumour chemosensitivity assay (ATP-TCA) to measure the activity of gefitinib alone or in combination with different cytotoxic drugs (cisplatin, gemcitabine, oxaliplatin and treosulfan) against a variety of solid tumours (n = 86), including breast, colorectal, oesophageal and ovarian cancer, carcinoma of unknown primary site, cutaneous and uveal melanoma, non-small cell lung cancer (NSCLC) and sarcoma.
  • To allow comparison between samples the IndexSUM was calculated based on the percentage tumour growth inhibition (TGI) at each test drug concentration (TDC).
  • CONCLUSION: The in vitro model suggests that gefitinib may have differential effects in response to concomitant cytotoxic chemotherapy with the agents tested during this study.
  • The mechanism involved may relate to the effect of TKIs on growth rate versus their effect on the ability of the cell to survive the stimulus to apoptosis produced by chemotherapy.
  • [MeSH-major] Busulfan / analogs & derivatives. Deoxycytidine / analogs & derivatives. Neoplasms / drug therapy. Quinazolines / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenosine Triphosphate / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Colorectal Neoplasms / drug therapy. Drug Screening Assays, Antitumor / methods. Female. Humans. Melanoma / drug therapy. Neoplasms, Unknown Primary / drug therapy. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Uveal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TREOSULFAN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1993 Jun;19(3):242-9 [8314382.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):241-50 [10454201.001]
  • [Cites] Lancet. 1996 Apr 20;347(9008):1066-71 [8602056.001]
  • [Cites] Anticancer Drugs. 1996 Aug;7(6):630-5 [8913430.001]
  • [Cites] Anticancer Drugs. 1998 Jan;9(1):51-7 [9491792.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):258-63 [10785475.001]
  • [Cites] Biochem J. 2000 Oct 15;351 Pt 2:289-305 [11023813.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4885-92 [11156248.001]
  • [Cites] Melanoma Res. 2001 Dec;11(6):601-9 [11725206.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2240-50 [11980995.001]
  • [Cites] Anticancer Drugs. 2002 Jul;13(6):625-30 [12172508.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:16-24 [12202784.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:31-9 [12202786.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2658-63 [12860941.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] J Cell Physiol. 2004 Feb;198(2):259-68 [14603528.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]
  • [Cites] BMC Cancer. 2003 Jul 3;3:19 [12841853.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513-8 [9811831.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1487-93 [10188895.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5276-82 [7585588.001]
  • (PMID = 15560844.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 8L70Q75FXE / Adenosine Triphosphate; B76N6SBZ8R / gemcitabine; CO61ER3EPI / treosulfan; G1LN9045DK / Busulfan; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC535559
  •  go-up   go-down


2. Tetzlaff ED, Correa AM, Baker J, Ensor J, Ajani JA: The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer; 2007 May 15;109(10):1989-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma.
  • BACKGROUND: Thromboembolic events (TEEs) are considered common in patients with gastroesophageal carcinoma, but their frequency at baseline and during chemotherapy is not known.
  • Because prophylactic anticoagulation results in improved overall survival (OS) of solid tumor patients, the authors hypothesized that TEEs at baseline and during chemotherapy would have an adverse effect on OS.
  • METHODS: The authors analyzed patients with advanced gastroesophageal carcinoma who were treated on 4 prospective chemotherapy Phase II/III trials.
  • At baseline, TEEs occurred in 5.3% of untreated patients compared with 8.5% of previously treated patients (who had received prior treatment for metastatic disease).
  • The median OS was only 3.9 months for patients who had a TEE at any time versus 8.7 months for patients who never developed a TEE (P = .007).
  • There was no associated between TEEs and the type of chemotherapy used.
  • CONCLUSIONS: The current results established that TEEs at baseline and/or during chemotherapy are frequent and result in poor OS for patients with advanced gastroesophageal carcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / mortality. Stomach Neoplasms / mortality. Thromboembolism / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 17397035.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Hori K, Saito S, Kubota K: A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer; 2002 May 20;86(10):1604-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.
  • In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and methylcholanthrene-induced primary tumours, to demonstrate that a novel water-soluble combretastatin A-4 derivative, AC7700, abruptly and irreversibly stopped tumour blood flow.
  • In the present study, we investigated whether AC7700 acts in the same way against solid tumours growing in the liver, stomach, kidney, muscle, and lymph nodes.
  • In a model of cancer chemotherapy against metastases, LY80 cells (2x10(6)) were injected into the lateral tail vein, and AC7700 at 10 mg x kg(-1) was injected i.v. five times at intervals of 2 days, starting on day 7 after tumour cell injection.
  • The change in tumour blood flow and the therapeutic effect of AC7700 on microtumours were observed directly by using Sato lung carcinoma implanted in a rat transparent chamber.
  • AC7700 caused a marked decrease in the tumour blood flow of all LY80 tumours developing in various tissues and organs and growth of all tumours including lymph node metastases and microtumours was inhibited.
  • These results demonstrate that AC7700 is effective for tumours growing in various tissues and organs and for metastases.
  • We conclude that tumour blood flow stanching induced by AC7700 may become an effective therapeutic strategy for all cancers, including refractory cancers because the therapeutic effect is independent of tumour site and specific type of cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma / drug therapy. Lung Neoplasms / drug therapy. Prodrugs / therapeutic use. Sarcoma, Yoshida / drug therapy. Serine / analogs & derivatives. Serine / therapeutic use. Vasoconstrictor Agents / therapeutic use
  • [MeSH-minor] Animals. Drug Screening Assays, Antitumor. Heart Neoplasms / blood supply. Heart Neoplasms / drug therapy. Kidney Neoplasms / blood supply. Kidney Neoplasms / drug therapy. Liver Neoplasms, Experimental / blood supply. Liver Neoplasms, Experimental / drug therapy. Lymphatic Metastasis. Male. Neoplasm Transplantation. Organ Specificity. Rats. Regional Blood Flow / drug effects. Skin Window Technique. Stomach Neoplasms / blood supply. Stomach Neoplasms / drug therapy. Tumor Cells, Cultured / transplantation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] comCopyright 2002 Cancer Research UK
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):1016-25 [10551333.001]
  • [Cites] Circ Res. 1964 Feb;14:164-87 [14118761.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1318-27 [10604728.001]
  • [Cites] Jpn J Cancer Res. 1999 Dec;90(12):1387-95 [10665658.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1833-43 [10974632.001]
  • [Cites] Biochem Pharmacol. 2001 Feb 1;61(3):253-70 [11172729.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):290-5 [11161390.001]
  • [Cites] Med Sci Monit. 2001 Jan-Feb;7(1):26-33 [11208488.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Pathol. 1975 Jun;116(2):65-72 [168332.001]
  • [Cites] Gan. 1979 Jun;70(3):383-4 [467900.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Feb;19(2):271-5 [6681772.001]
  • [Cites] J Natl Cancer Inst. 1989 Feb 1;81(3):216-20 [2911084.001]
  • [Cites] Experientia. 1989 Feb 15;45(2):209-11 [2920809.001]
  • [Cites] J Natl Cancer Inst. 1989 Jul 5;81(13):1005-13 [2733044.001]
  • [Cites] Acta Anat (Basel). 1989;136(1):27-33 [2816252.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Oct;25(10):1419-24 [2591434.001]
  • [Cites] Jpn J Cancer Res. 1990 Mar;81(3):279-88 [1693611.001]
  • [Cites] Eur J Cancer. 1991;27(4):482-7 [1827725.001]
  • [Cites] Jpn J Cancer Res. 1991 Nov;82(11):1309-16 [1752787.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1320-4 [8343277.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):870-2 [8313372.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1163-8 [7779706.001]
  • [Cites] Int J Cancer. 1996 Jan 26;65(3):360-4 [8575858.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S86-8 [8763854.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1829-34 [9157969.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] J Med Chem. 1998 Jul 30;41(16):3022-32 [9685242.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):895-8 [9845117.001]
  • [Cites] Bioorg Med Chem Lett. 1998 Nov 17;8(22):3153-8 [9873694.001]
  • [Cites] Bioorg Med Chem Lett. 1998 Dec 1;8(23):3371-4 [9873736.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1626-34 [10197639.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1A):189-95 [10226542.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):1026-38 [10551334.001]
  • (PMID = 12085211.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / AC 7700; 0 / Antineoplastic Agents, Phytogenic; 0 / Prodrugs; 0 / Vasoconstrictor Agents; 452VLY9402 / Serine
  • [Other-IDs] NLM/ PMC2746587
  •  go-up   go-down


Advertisement
4. Chen CN, Cheng YM, Lin MT, Hsieh FJ, Lee PH, Chang KJ: Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer. Ann Surg; 2002 Apr;235(4):512-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY BACKGROUND DATA: Many studies have reported a significant association between the degree of MVD-evaluated angiogenesis with the clinicopathologic factors and prognosis of patients with various solid tumors.
  • All these studies were accomplished on tissue sections retrospectively obtained from surgical specimens.
  • However, an in vivo method to assess tumor angiogenesis for human malignancies is highly desirable for diagnostic purpose, treatment planning, and follow-up.
  • The CDVI is a new ultrasound parameter for evaluating in vivo angiogenesis, has a good correlation with status of lymph node metastasis in cervical carcinoma, and can predict distant metastasis and survival in colon cancer patients.
  • Thus, the CDVI may be helpful in selecting patients with gastric cancer for neoadjuvant chemotherapy and/or anti-angiogenic therapy.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / mortality. Neovascularization, Pathologic / ultrasonography. Stomach Neoplasms / blood supply. Stomach Neoplasms / mortality. Ultrasonography, Doppler, Color / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Jul 15;78(2):226-31 [8673996.001]
  • [Cites] Cancer. 1963 Apr;16:453-67 [13958548.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):766-72 [8795580.001]
  • [Cites] J Immunol. 1997 Feb 1;158(3):1302-9 [9013973.001]
  • [Cites] Cancer. 1998 May 15;82(10):1881-6 [9587120.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1189-96 [9740085.001]
  • [Cites] Invest Radiol. 1999 Mar;34(3):194-8 [10084663.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):651-7 [10091738.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] Pharmacol Rev. 2000 Jun;52(2):237-68 [10835101.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2892-7 [10850434.001]
  • [Cites] Eur J Cancer. 1973 Mar;9(3):223-7 [4787857.001]
  • [Cites] Cancer Res. 1974 May;34(5):997-1004 [4841969.001]
  • [Cites] Cancer Res. 1976 Mar;36(3):889-94 [1253177.001]
  • [Cites] Radiology. 1979 Dec;133(3 Pt 1):677-80 [504647.001]
  • [Cites] AJR Am J Roentgenol. 1981 Nov;137(5):969-72 [6975024.001]
  • [Cites] J Natl Cancer Inst. 1983 Aug;71(2):275-9 [6576187.001]
  • [Cites] Radiology. 1988 Jan;166(1 Pt 1):57-62 [2447604.001]
  • [Cites] Gastrointest Radiol. 1988 Jul;13(3):197-9 [3290033.001]
  • [Cites] Arch Surg. 1989 Mar;124(3):314-8 [2919965.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Nature. 1990 Dec 6;348(6301):555-7 [1701033.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] Eur J Cancer. 1991;27(6):781-5 [1712608.001]
  • [Cites] Int J Cancer. 1991 Sep 9;49(2):203-7 [1879965.001]
  • [Cites] Radiology. 1991 Oct;181(1):241-4 [1887039.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):371-4 [7690738.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44 [8230264.001]
  • [Cites] Int J Cancer. 1993 Nov 11;55(5):739-44 [8244569.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1251-6 [7508817.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):921-6 [7521279.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2068-101 [7522621.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):609-16 [7993836.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):477-81 [7531224.001]
  • [Cites] Radiology. 1995 Apr;195(1):86-90 [7534429.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4575-80 [7553632.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5049-53 [7585550.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Ann Surg. 1995 Dec;222(6):695-9 [8526575.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2671-6 [8653715.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1255-61 [10098768.001]
  • [Cites] J Ultrasound Med. 1999 Aug;18(8):547-51 [10447080.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3436-40 [8758908.001]
  • (PMID = 11923607.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1422466
  •  go-up   go-down


5. Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, Mason DP, Rodriguez CP, Ives DI: Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol; 2009 Oct;4(10):1264-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Concurrent chemoradiotherapy was begun between 6 and 10 weeks after surgery and consisted of radiotherapy (1.8 Gy/d to a planned dose of 50.4-59.4 Gy), concurrent with two cycles of 5-fluorouracil (1000 mg/m/d) and cisplatin (20 mg/m/d), both given as 4-day continuous intravenous infusions during the first and fourth weeks of the radiation.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophagogastric Junction / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Esophagectomy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prospective Studies. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19668013.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Gao H, Wang JY, Shen XZ, Deng YH, Zhang W: Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor. World J Gastroenterol; 2004 Jul 15;10(14):2010-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Particle size, shape and drug content were examined.
  • Female BABL/c nude mice were implanted with MKN-45 gastric carcinoma tissues subcutaneously to establish human gastric carcinoma model.
  • Magnets (2.5 T) were implanted into the tumor masses in all of the mice one day before the therapy.
  • Above-mentioned drugs were administered intravenously to the mice of every group on the first day and sixth day.
  • When the mice were sacrificed, tumor weight was measured, and the assay of granulocyte- macrophage colony forming-unit (CFU-GM) was performed on semi-solid culture.
  • The inhibitory rates of ACM (8 mg/kg bm), high dosage of MPNS-ACM (8 mg/kg bm), low dosage of MPNS-ACM (1.6 mg/kg bm) and MPNS on human gastric carcinoma in nude mice were 22.63%, 52.55%, 30.66% and 10.22%, respectively.
  • [MeSH-major] Aclarubicin / administration & dosage. Antibiotics, Antineoplastic / administration & dosage. Enbucrilate. Magnetics. Nanotechnology. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15237424.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Capsules; 74KXF8I502 / Aclarubicin; F8CEP82QNP / Enbucrilate
  • [Other-IDs] NLM/ PMC4572323
  •  go-up   go-down


7. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL, Moore PA, Ruben SM, Carter PJ: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer; 2008 Jul 8;99(1):100-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers.
  • CD133/prominin-1 is a pentaspan transmembrane glycoprotein overexpressed in various solid tumours including colorectal and glioblastomas.
  • A murine anti-human CD133 antibody (AC133) conjugated to a potent cytotoxic drug, monomethyl auristatin F (MMAF), effectively inhibited the growth of Hep3B hepatocellular and KATO III gastric cancer cells in vitro with IC(50) values of 2-7 ng ml(-1).
  • The anti-CD133-drug conjugate (AC133-vcMMAF) was shown to internalise and colocalised with the lysosomal marker CD107a in the sensitive cell lines.
  • Anti-CD133-drug conjugate treatment resulted in significant delay of Hep3B tumour growth in SCID mice.
  • Anti-CD133 antibody-drug conjugates warrant further evaluation as a therapeutic strategy to eradicate CD133+ tumours.
  • [MeSH-minor] Antigens, CD / biosynthesis. Apoptosis / drug effects. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. Hepatocytes. Humans. Hybridomas. Immunohistochemistry. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / metabolism. Stomach Neoplasms / drug therapy. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2005 Apr;37(4):715-9 [15694831.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10540-7 [16484228.001]
  • [Cites] Leukemia. 2000 Apr;14(4):770-2 [10764169.001]
  • [Cites] Cell Biol Toxicol. 2002;18(3):157-73 [12083422.001]
  • [Cites] Bioconjug Chem. 2002 Jul-Aug;13(4):855-69 [12121142.001]
  • [Cites] J Virol. 2002 Nov;76(22):11440-6 [12388705.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:141-51 [12799292.001]
  • [Cites] Nat Biotechnol. 2003 Jul;21(7):778-84 [12778055.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1458-65 [12714494.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):583-5 [15100335.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1435-7 [10075457.001]
  • [Cites] Blood. 1999 Jul 15;94(2):832-3 [10438201.001]
  • [Cites] Leukemia. 1999 Sep;13(9):1466-7 [10483002.001]
  • [Cites] Mol Cancer Ther. 2004 Nov;3(11):1493-501 [15542788.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7842-51 [15585616.001]
  • [Cites] Cell Tissue Res. 2005 Jan;319(1):15-26 [15558321.001]
  • [Cites] J Cell Sci. 2005 Jul 1;118(Pt 13):2849-58 [15976444.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):2890-9 [16116175.001]
  • [Cites] Nat Clin Pract Oncol. 2005 May;2(5):224-5 [16264940.001]
  • [Cites] Cell Prolif. 2005 Dec;38(6):363-74 [16300650.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Blood. 2006 Jan 15;107(2):431-4 [16150939.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1474-82 [16818506.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 20;355(4):855-9 [17307142.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):186-95 [17593025.001]
  • [Cites] FASEB J. 2007 Dec;21(14):3777-85 [17625071.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):704-14 [15897234.001]
  • [Cites] Bioconjug Chem. 2006 Jan-Feb;17(1):114-24 [16417259.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2328-37 [16489038.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3214-21 [16540673.001]
  • [CommentIn] Br J Cancer. 2009 Apr 21;100(8):1365-6; author reply 1367 [19367288.001]
  • (PMID = 18542072.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Glycoproteins; 0 / Peptides
  • [Other-IDs] NLM/ PMC2453027
  •  go-up   go-down


8. Tanaka F: UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg Today; 2007;37(11):923-43
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.
  • UFT (tegafur and uracil) is an oral anticancer drug that has been developed in Japan.
  • Therefore, a variety of adjuvant chemotherapy trials with UFT have been conducted, and results of well-designed randomized controlled trials have recently shown a survival benefit of postoperative UFT treatment in resected lung, gastric, colorectal, and breast cancer.
  • In the present article, postoperative adjuvant trials with UFT-containing chemotherapy are reviewed, and the mechanism of action and future directions are also discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Colonic Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Postoperative Care / methods. Rectal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Female. Humans. Male. Tegafur / therapeutic use. Treatment Outcome. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1987 Jul;78(7):748-55 [3114201.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):792-9 [15681523.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Mar;33(3):300-6 [16531708.001]
  • [Cites] Eur J Surg Oncol. 1995 Feb;21(1):69-77 [7851558.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):921-6 [7521279.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42 Suppl:S68-70 [9750032.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2671-6 [8653715.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):607-15 [16880781.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):484-92 [14752071.001]
  • [Cites] Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):68-71 [11098498.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S25-31 [15309511.001]
  • [Cites] Jpn J Clin Oncol. 1995 Jun;25(3):91-103 [7596054.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):21-9 [3276900.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Mar;33(3):307-12 [16531709.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] N Engl J Med. 2006 Nov 2;355(18):1920-2 [17079767.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):976-83 [12637460.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2185-91 [10473104.001]
  • [Cites] Int J Clin Oncol. 2001 Oct;6(5):236-41 [11723745.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Apr;15(4):438-43 [10371118.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8313-21 [16293862.001]
  • [Cites] Lung Cancer. 2003 Mar;39(3):289-96 [12609567.001]
  • [Cites] J Surg Oncol. 1995 Sep;60(1):59-64 [7666668.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] Cancer Sci. 2004 Apr;95(4):371-6 [15072598.001]
  • [Cites] N Engl J Med. 2005 Jun 2;352(22):2302-13 [15930421.001]
  • [Cites] Thorac Cardiovasc Surg. 2005 Apr;53(2):118-21 [15786012.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):141-5 [10901361.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Aug;21(11):1800-5 [8080299.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2728-36 [10561347.001]
  • [Cites] Chest. 1994 Dec;106(6 Suppl):377S-381S [7988268.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3410-5 [11705856.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2877-85 [9704742.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):877-8 [8151332.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3386-91 [16585158.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8671-8 [16314627.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2172-84 [15800310.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5381-7 [17135639.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Mar;33(3):318-23 [16531711.001]
  • [Cites] Lung Cancer. 2005 Mar;47(3):385-94 [15713522.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(2):113-24 [10573104.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5664-71 [17116941.001]
  • [Cites] Langenbecks Arch Surg. 1998 Dec;383(6):409-15 [9921940.001]
  • [Cites] Oncology. 2003;64(2):146-53 [12566912.001]
  • [Cites] Jpn J Clin Oncol. 1998 Jan;28(1):77-80 [9491146.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1779-87 [16931911.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Aug;18(2):147-55 [10925222.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2602-6 [8653704.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3686-96 [15897552.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Jun;33(6):736-41 [16770090.001]
  • [Cites] Br J Cancer. 1990 Dec;62(6):1023-5 [2257207.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2496-503 [7909277.001]
  • [Cites] Gan. 1979 Apr;70(2):209-14 [381088.001]
  • [Cites] J Surg Oncol. 2002 Oct;81(2):87-92 [12355409.001]
  • [Cites] Ann Surg Oncol. 2004 Jun;11(6):612-8 [15150069.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] Int J Mol Med. 2003 Dec;12(6):839-44 [14612954.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):205-11 [8996521.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):719-27 [16945766.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1048-54 [8648356.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4999-5006 [16051951.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Sep;12(3):372-9 [9332914.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):237-44 [16675478.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2085-8 [9748123.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] N Engl J Med. 1976 Feb 19;294(8):405-10 [1246307.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1431-9 [12668651.001]
  • [Cites] Gan. 1979 Jun;70(3):353-9 [467897.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):817-21 [16969350.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):112-8 [10862203.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1569-83 [16148022.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Chemother. 2006 Jun;18(3):311-7 [17129844.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2772-9 [10894878.001]
  • [Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):81-3 [15603857.001]
  • [Cites] Langenbecks Arch Surg. 2002 Mar;386(8):575-81 [11914933.001]
  • [Cites] Lancet. 1998 Jul 25;352(9124):257-63 [9690404.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):371-4 [7690738.001]
  • [Cites] Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):82-6 [11098502.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Angiogenesis. 2001;4(3):163-73 [11911014.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Oct;33(10):1423-9 [17033231.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):85-94 [15949594.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):21-7 [12004845.001]
  • [Cites] N Engl J Med. 1985 Jun 6;312(23 ):1465-72 [2859523.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):263-9 [11161386.001]
  • [Cites] Int J Clin Oncol. 2004 Apr;9(2):98-106 [15108041.001]
  • [Cites] Chest. 1997 Oct;112(4 Suppl):242S-248S [9337297.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:110-6 [16897984.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Curr Pharm Biotechnol. 2000 Sep;1(2):137-64 [11467334.001]
  • [Cites] Lung Cancer. 2003 May;40(2):181-6 [12711119.001]
  • [Cites] Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):74-81 [9348574.001]
  • [Cites] Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):91-5 [10442372.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):816-20 [12942110.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):939-43 [11592762.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] N Engl J Med. 2006 Feb 23;354(8):809-20 [16495393.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):75-80 [15598942.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;22(4):333-8 [3139315.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1368-74 [19204202.001]
  • (PMID = 17952521.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  • [Number-of-references] 150
  •  go-up   go-down


9. Yoshimura F, Sakurai Y, Inaba K, Ishida Y, Taniguchi K, Isogaki J, Kanaya S, Komori Y, Uyama I: [Clinical characteristics of cases showing complete regression of the primary tumor after S-1 combined with cisplatin administered as neoadjuvant chemotherapy in advanced gastric carcinoma]. Gan To Kagaku Ryoho; 2010 Nov;37(11):2087-92
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of cases showing complete regression of the primary tumor after S-1 combined with cisplatin administered as neoadjuvant chemotherapy in advanced gastric carcinoma].
  • Although neoadjuvant chemotherapy has been recognized as an important option to improve the clinical outcome of patients with advanced gastric carcinoma, the precise histological effects of neoadjuvant chemotherapy on the primary and metastatic foci have not well been documented.
  • The aim of the present study was thus to evaluate histological effects of S-1-based neoadjuvant chemotherapy on the resected specimens of gastric carcinoma and regional lymph nodes, and primarily to focus on the histology of the cases showing complete regression of the primary cancer cells.
  • A total of 164 patients received neoadjuvant chemotherapy with the combination of S-1 (80 to 120 mg/body/day for 3 weeks) and cisplatin (35 to 60 mg/m2 on day 8).
  • A total of 77 cases (46.9%) responded to the neoadjuvant chemotherapy and 9 cases (5.5%) showed a complete regression of the primary gastric carcinoma.
  • Five of 9 cases were solid-type poorly-differentiated adenocarcinoma (por1), and the incidence of responders was the highest in patients with por1.
  • S-1-based neoadjuvant chemotherapy has significant histological effects on gastric carcinoma and metastatic foci, which may further improve long-term clinical outcome in patients with advanced gastric carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Aged. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084805.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Yamaguchi H, Tanaka F, Sadanaga N, Ohta M, Inoue H, Mori M: Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. Int J Oncol; 2003 Dec;23(6):1697-702
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells.
  • Interestingly, the expression of the CD40 in various types of carcinoma cells was often observed and conveys signals regulating diverse cellular responses, ranging from proliferation to growth suppression.
  • Thus, the biologic role of the CD40-CD40L interaction in solid tumors is still controversial.
  • In this study, we investigated the expression and function of the CD40 in gastric carcinoma cells.
  • In 3-4,5 dimethylthiozol-2-yl-2,5-diphenyl tetrazolium bromide (MTT) assay and Annexin V/propidium iodide staining, CD40 stimulation using a soluble form of CD40 ligand did not affect cell viability, but significantly inhibited Fas-mediated or chemotherapy-mediated apoptosis in three CD40-positive gastric cancer cell lines.
  • Moreover, in migration assay, CD40 stimulation induced an elevation of cell motility in CD40-positive gastric carcinoma cells.
  • Our results show that the CD40 expression on gastric carcinoma makes cells less vulnerable to apoptosis induced by Fas or chemotherapy.
  • These results suggest that the CD40 expression on gastric carcinoma may be associated with cell survival and elevation of cell motility.
  • [MeSH-major] Antigens, CD40 / metabolism. Antigens, CD95 / metabolism. Apoptosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. CD40 Ligand / metabolism. Camptothecin / pharmacology. Carcinoma / drug therapy. Carcinoma / metabolism. Carcinoma / pathology. Cell Division. Cell Line, Tumor. Cell Membrane / metabolism. Cell Movement. Cell Survival. Flow Cytometry. Humans. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14612943.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Antigens, CD95; 0 / Antineoplastic Agents, Phytogenic; 0 / Tetrazolium Salts; 0 / Thiazoles; 147205-72-9 / CD40 Ligand; 298-93-1 / thiazolyl blue; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Kim DY, Lee KW, Yun T, Park SR, Jung JY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK: Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol; 2003 Dec;33(12):608-12
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone.
  • OBJECTIVE: To compare the efficacy of intrathecal methotrexate single therapy with three-drug combination therapy in patients with leptomeningeal carcinomatosis.
  • METHODS: Fifty-five patients who had pathologically proven leptomeningeal carcinomatosis of a solid tumor were evaluated in terms of pathological response.
  • RESULTS: Primary sites of the tumor were the lung (n = 33), breast (n = 13) and stomach (n = 5).
  • The cytological response rate to intrathecal chemotherapy was significantly higher in the MHA group than in the M group (38.5 vs 13.8%, P = 0.036).
  • CONCLUSION: Combination intrathecal chemotherapy with methotrexate, cytosine arabinoside and hydrocortisone showed more favorable effects than methotrexate single therapy for leptomeningeal carcinomatosis in solid tumors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Meningeal Neoplasms / drug therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / pathology. Cytarabine / administration & dosage. Drug Administration Schedule. Female. Humans. Hydrocortisone / administration & dosage. Injections, Spinal. Male. Middle Aged. Retrospective Studies. Survival Rate

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14769837.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Shibata N, Eto TA, Hotokezaka M, Iwamura T, Chijiiwa K: [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1159-62
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1].
  • After placement of the bilateral ureteral stents, she was treated with combined chemotherapy of biweekly paclitaxel (120 mg/m2, day 1, day 15) and TS-1 (80 mg/day, days 1-14 with 2-weeks rest).
  • Subjective symptoms were relieved after one course of the chemotherapy.
  • After 3 courses, computed tomography showed markedly reduced supra-clavicular lymph node metastases and no ascites.
  • These findings suggested that partial response on Response Evaluation Criteria in Solid Tumors (RECIST) was obtained.
  • After the first course, the treatment was continued on an outpatient basis.
  • There were no adverse effects over grade 2 throughout six courses of the chemotherapy.
  • The biweekly paclitaxel and TS-1 chemotherapy may well be an effective treatment for advanced schirrhous gastric cancer with carcinomatous peritonitis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Ascites. Constriction, Pathologic. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Peritonitis / etiology. Pyridines / administration & dosage. Rectal Diseases / etiology. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121920.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Kumagai K, Saikawa Y, Fukuda K, Ito R, Igarashi T, Tsuwano S, Nakamura R, Takahashi T, Takeuchi H, Kitagawa Y: Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy. Int J Clin Oncol; 2009 Aug;14(4):372-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy.
  • Abdominal computed tomography showed multiple intraperitoneal nodules consistent with peritoneal dissemination of the gastric cancer.
  • The patient's inability to tolerate oral intake was a contraindication to using S-1 chemotherapy, currently one of the most effective medications used for gastric cancer in Japan.
  • Her bowel obstruction was sufficiently attenuated on the seventh day after the initiation of treatment with OA to permit the initiation of oral S-1, along with low-dose cisplatin (CDDP) and radiation.
  • Radiation therapy (2 Gy/day for 5 days/week) was performed with the chemotherapy.
  • Despite no change being shown on her imaging findings with the chemotherapy, the patient's bowel obstruction resolved and she was able to tolerate both liquids and solid food orally.
  • Seven months after beginning the chemotherapy, she was still doing well on outpatient chemotherapy with S-1 and CDDP, and had no decline in her quality of life or progression of her disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Agents / therapeutic use. Intestinal Obstruction / drug therapy. Octreotide / therapeutic use. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / secondary. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Combinations. Female. Humans. Neoplasm Staging. Oxonic Acid / administration & dosage. Radiotherapy, Adjuvant. Tegafur / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pain Symptom Manage. 2004 Oct;28(4):412-6 [15471659.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):830-5 [16174232.001]
  • [Cites] J Pain Symptom Manage. 1997 Jun;13(6):352-5 [9204656.001]
  • [Cites] Jpn J Clin Oncol. 2003 Nov;33(11):584-8 [14711984.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:99-105 [16897982.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Sep;31(9):1377-82 [15446560.001]
  • [Cites] J Pain Symptom Manage. 2005 Dec;30(6):563-9 [16376743.001]
  • [Cites] Eur J Cancer. 1994;30A(1):28-30 [7511400.001]
  • [Cites] J Pain Symptom Manage. 2000 Jan;19(1):23-34 [10687323.001]
  • [Cites] Palliat Med. 2006 Oct;20(7):715-6 [17060271.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):381-6 [12579276.001]
  • [Cites] Support Care Cancer. 2000 May;8(3):188-91 [10789958.001]
  • [Cites] J Pediatr Surg. 2007 Jan;42(1):259-60 [17208578.001]
  • [Cites] Gynecol Oncol. 1996 Jun;61(3):345-8 [8641613.001]
  • [Cites] Oncol Rep. 2005 May;13(5):865-70 [15809751.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Gastric Cancer. 2007;10(1):29-34 [17334715.001]
  • [Cites] Chemotherapy. 2001;47 Suppl 2:54-61 [11275702.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Pain Symptom Manage. 2007 Feb;33(2):217-23 [17280927.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1228-3 [17464538.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Jul;29(7):1241-5 [12146007.001]
  • (PMID = 19705252.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Gastrointestinal Agents; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


14. Kusayanagi S, Konishi K, Miyasaka N, Sasaki K, Kurahashi T, Kaneko K, Akita Y, Yoshikawa N, Kusano M, Yamochi T, Kushima M, Mitamura K: Primary small cell carcinoma of the stomach. J Gastroenterol Hepatol; 2003 Jun;18(6):743-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of the stomach.
  • We report on an 80-year-old man with primary gastric small cell carcinoma (SmCC).
  • An upper gastrointestinal examination revealed an irregularly ulcerated tumor, 60 mm in diameter, on the lesser curvature of the stomach body extending to the cardia.
  • An endoscopic biopsy revealed a solid proliferation of intermediate-sized tumor cells with hyperchromatic nuclei and scanty cytoplasm.
  • Most patients with gastric SmCC die within 1 year of diagnosis.
  • Although a standard treatment for gastric SmCC has not been established, intensive chemotherapy should be considered to promote long-term survival.
  • We believe that careful examination, including immunohistochemical investigation, is necessary for determining the therapeutic strategy whenever gastric SmCC is suspected during endoscopy.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12753162.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Chromogranin A; 0 / Chromogranins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 27
  •  go-up   go-down


15. Hosoya Y, Nagai H, Koinuma K, Yasuda Y, Kaneko Y, Saito K: A case of aggressive neuroendocrine carcinoma of the stomach. Gastric Cancer; 2003;6(1):55-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of aggressive neuroendocrine carcinoma of the stomach.
  • An 18 cm x 16 cm x 10 cm tumor of the stomach, invading the left lobe of the liver, pancreatic body and tail, and transverse colon, with peritoneal deposits on the major omentum, was resected by total gastrectomy plus left hepatic lobectomy, transverse colectomy, distal pancreatectomy, splenectomy, and omentectomy.
  • Histopathologically, the tumor consisted of large uniform cells with significant nuclear atypia, showing solid growth patterns with occasional small nests without adenocarcinoma components.
  • Immunohistochemical investigations of the neoplastic cells confirmed the tumor as a neuroendocrine (NE) carcinoma. molecular analyses disclosed loss of heterozygosity at the MEN1 gene locus on chromosome 11q13.
  • Following percutaneous transhepatic biliary drainage, intensive chemotherapy (20 mg/m(2) cisplatin on days 1-5 div, 100 mg/m(2) etoposide on days 1, 3, and 5 div, and 800 mg/m(2) 5-fluorouracil on days 1-5 bolus iv) was started.
  • The recurrent tumor shrank dramatically, and could not be detected on image modalities after five courses of chemotherapy.
  • An aggressive form of NE carcinoma has been known to be associated with an extremely poor prognosis.
  • However, it is notable that treatment with extensive surgery and intensive chemotherapy could contribute to an improvement in quality of life even if the beneficial effect lasted for only half a year.
  • [MeSH-major] Carcinoma, Neuroendocrine / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Fluorouracil / administration & dosage. Gastrectomy. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Middle Aged. Omentum / pathology. Omentum / radiography. Omentum / surgery. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12673427.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Dempke W, von Poblozki A, Kellner O, Wolf HH, Schmoll HJ: [Hemorrhagic diathesis as initial symptom of stomach carcinoma]. Wien Klin Wochenschr; 2000 Dec 22;112(24):1053-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemorrhagic diathesis as initial symptom of stomach carcinoma].
  • BACKGROUND: Microangiopathic hemolytic anemia (MAHA) and disseminated intravasal coagulation (DIC) as initial paraneoplastic symptoms of a solid tumor present a rare clinical situation.
  • Histologically, a signet-ring cell carcinoma was diagnosed.
  • Final diagnosis stated a multilocular metastasising gastric cancer with infiltration of bone, peritoneum and dura and signet-cell infiltration of the bone marrow.
  • Parallel to initial symptomatic therapy of coagulopathy, systemic cytostatic therapy with CDDP and VP-16 was initiated.
  • After histologic confirmation of the diagnosis, weekly therapy with 5-FU (2600 mg/m2) and folinic acid (500 mg/m2) according to the Ardalan protocol was performed.
  • Although the chemotherapy dose had to be reduced due to prolonged neutropenia, the disturbances of hemostasis resolved completely resulting in reduced substitution rates with fresh frozen plasma (FFP) and platelets.
  • However, it should be followed by specific therapy of malignancy, since tumor-induced metabolites (e.g. mucin) maintain the alteration of hemostasis.
  • Chemotherapy may therefore be the best strategy to prevent complications such as MAHA and DIC.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Hemorrhagic Disorders / etiology. Precancerous Conditions / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Algorithms. Anemia, Hemolytic / diagnosis. Anemia, Hemolytic / etiology. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Bone Marrow Neoplasms / pathology. Bone Marrow Neoplasms / secondary. Cisplatin / administration & dosage. Diagnosis, Differential. Disseminated Intravascular Coagulation / diagnosis. Disseminated Intravascular Coagulation / etiology. Etoposide / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Middle Aged. Neoplasm Metastasis. Stomach / pathology. Thrombocytopenia / diagnosis

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11204317.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Au WY, Yeung CK, Chan HH, Wong RW, Shek TW: CD30-positive cutaneous T-cell lymphoma with concurrent solid tumour. Br J Dermatol; 2002 Jun;146(6):1091-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive cutaneous T-cell lymphoma with concurrent solid tumour.
  • Although an increased incidence of solid tumours has been reported in patients with CD30+ non-Hodgkin lymphoma of the skin, reports of concurrent malignancies are rare in CD30+ CTCL.
  • We report two patients with CD30+ CTCL who, respectively, had concurrent disseminated gastric carcinoma and bilateral ovarian teratoma.
  • The CTCL responded completely to chemotherapy in one patient, who eventually succumbed to gastric cancer.
  • A possible relationship between the lymphoma and the solid tumours is discussed.
  • [MeSH-major] Antigens, CD30 / analysis. Antigens, Neoplasm / analysis. Lymphoma, T-Cell, Cutaneous / immunology. Neoplasms, Multiple Primary / immunology. Skin Neoplasms / immunology. Stomach Neoplasms / immunology. Uterine Neoplasms / immunology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12072086.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, Neoplasm
  •  go-up   go-down


18. Lissoni P: Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris); 2007 Apr-May;55(3-4):201-4
Hazardous Substances Data Bank. MELATONIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
  • Therefore, MLT could be useful in the treatment of human neoplasms, either alone or in association with chemotherapy.
  • The present study was performed to evaluate the influence of a concomitant MLT administration on efficacy and toxicity of several chemotherapeutic combinations in metastatic solid tumor patients, suffering from non-small cell lung cancer (NSCLC) or gastrointestinal tumors.
  • The study included 370 patients who were randomized to receive chemotherapy alone or chemotherapy plus MLT (20 mg/day orally in the evening every day).
  • The overall tumor regression rate achieved in patients concomitantly treated with MLT was significantly higher than that found in those treated with chemotherapy alone.
  • These results confirm in human the anticancer therapeutic properties of the pineal hormone MLT, which may enhance the efficacy of the standard anticancer chemotherapies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melatonin / therapeutic use. Neoplasms / drug therapy. Pinealoma / drug therapy
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Drug Therapy, Combination. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Neoplasm Metastasis / drug therapy. Pineal Gland / secretion. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17446010.001).
  • [ISSN] 0369-8114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; JL5DK93RCL / Melatonin
  •  go-up   go-down


19. Kanzaki A, Nakayama K, Miyashita H, Shirata S, Nitta Y, Oubu M, Higashimoto M, Mutoh M, Mori S, Konno S, Ogawa K, Toi M, Takebayashi Y: Mutation analysis of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinomas. Anticancer Res; 2003 Mar-Apr;23(2C):1913-5
Hazardous Substances Data Bank. COPPER, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinomas.
  • A major obstacle in the treatment of human solid carcinomas is the intrinsic/acquired resistance to cisplatin-based chemotherapy.
  • Copper-transporting P-type adenosine triphosphatase (ATP7B) has been reported to be associated with cisplatin resistance in vitro.
  • ATP7B is overexpressed in human solid carcinomas such as breast, gastric and oral squamous cell carcinomas.
  • These results indicate that the analysis of the ATP7B gene and/or protein will be helpful for the choice of chemotherapy in patients with human solid carcinomas.
  • [MeSH-minor] Base Sequence. Binding Sites. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Copper / metabolism. DNA Mutational Analysis. Drug Resistance, Neoplasm. Humans. Mouth Neoplasms / drug therapy. Mouth Neoplasms / genetics. Mouth Neoplasms / metabolism. Protein Structure, Tertiary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820478.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cation Transport Proteins; 789U1901C5 / Copper; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.3.4 / Wilson disease protein
  •  go-up   go-down


20. Heinemann V, Moosmann N: [Neoadjuvant and adjuvant therapies for solid tumours]. MMW Fortschr Med; 2007 Sep 6;149(35-36):27-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant and adjuvant therapies for solid tumours].
  • Today adjuvant or neoadjuvant therapies are standard treatment for many types of cancer.
  • Chemotherapy, radiotherapy, hormone therapy or immunotherapy applied before, during or after an operation can lower the risk of relapse and hence, increase the chances of a cure.
  • After neoadjuvant therapy, frequently the organ does not have to be removed in the subsequent operation.
  • Depending on the risk of relapse, adjuvant therapies are employed after due consideration of benefit, risk and duration of treatment.
  • [MeSH-major] Chemotherapy, Adjuvant. Neoadjuvant Therapy. Neoplasms / therapy. Radiotherapy, Adjuvant
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / surgery. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophageal Neoplasms / surgery. Female. Humans. Informed Consent. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Lung Neoplasms / surgery. Male. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery. Prognosis. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Risk Factors. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944281.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 0
  •  go-up   go-down


21. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K: Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol; 2003 Oct;33(10):533-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
  • However, the recent development of new classes of anti-cancer agents and progress in imaging technology have required new methodology to evaluate response to treatment.
  • Recently, the Response Evaluation Criteria in Solid Tumors Group (RECIST) proposed new guidelines using unidimensional measurement.
  • CONCLUSIONS: We conclude that the new RECIST guidelines are comparable to the old response criteria in evaluating response in solid tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials, Phase II as Topic / standards. Guidelines as Topic. Neoplasms / drug therapy
  • [MeSH-minor] Breast Neoplasms / drug therapy. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Evaluation Studies as Topic. Humans. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Retrospective Studies. Stomach Neoplasms / drug therapy. World Health Organization

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14623923.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Katsimbri PP, Bamias AT, Froudarakis ME, Peponis IA, Constantopoulos SH, Pavlidis NA: Endobronchial metastases secondary to solid tumors: report of eight cases and review of the literature. Lung Cancer; 2000 May;28(2):163-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial metastases secondary to solid tumors: report of eight cases and review of the literature.
  • Endobronchial metastases (EBM) secondaries to extrapulmonary solid malignant tumors are rare.
  • Since 1990 we have treated eight patients with EBM secondary to renal adenocarcinoma (three cases), colon adenocarcinoma (two cases), gastric adenocarcinoma (one case), bladder carcinoma (one case) and basal cell carcinoma (one case).
  • The median interval from the diagnosis of the primary tumour was 41 months.
  • Five patients were treated with external radiotherapy with symptomatic improvement while two patients had chemotherapy and one patient underwent surgical resection of the metastasis.
  • Systemic treatment was used in six cases with no significant effect on EBM.
  • Median survival after EBM diagnosis was 9 months with one patient surviving 3.5 years and two patients still alive at 1 year.
  • In conclusion, EBM usually represent a late manifestation requiring differential diagnosis from a primary lung cancer.
  • Local treatment may result in symptomatic improvement but prognosis is generally poor averaging 1-2 years in most series.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / pathology. Diagnosis, Differential. Female. Humans. Kidney Neoplasms / pathology. Male. Middle Aged. Prognosis. Stomach Neoplasms / pathology. Survival Analysis. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2001 Feb-Mar;31(2-3):351-2 [11305261.001]
  • (PMID = 10717334.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] IRELAND
  • [Number-of-references] 26
  •  go-up   go-down


23. Namikawa T, Kobayashi M, Okabayashi T, Ozaki S, Nakamura S, Yamashita K, Ueta H, Miyazaki J, Tamura S, Ohtsuki Y, Araki K: Primary gastric small cell carcinoma: report of a case and review of the literature. Med Mol Morphol; 2005 Dec;38(4):256-61
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for gastric small cell carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric small cell carcinoma: report of a case and review of the literature.
  • A 52-year-old man suffering from a pure-type primary gastric small cell carcinoma was treated with surgery and combination chemotherapy.
  • The small cell carcinoma, approximately 6.5 cm in diameter, was situated in the posterior wall of the antrum and there were no distant metastases.
  • Histological examination revealed a solid pattern of proliferation of small cells with hyperchromatic, round nuclei and scant cytoplasm.
  • Following surgery, the patient was treated with adjuvant chemotherapy consisting of cisplatin and etoposide.
  • We review 107 published cases of primary gastric small cell carcinoma, an extremely rare disease first reported in 1976.
  • Small cell carcinoma is an aggressive, malignant tumor.
  • Intensive chemotherapy is essential for patient survival even when curative surgical resection is carried out.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 1990 Apr;35(4):513-8 [2156662.001]
  • [Cites] Am J Gastroenterol. 1988 Oct;83(10):1176-9 [2844080.001]
  • [Cites] Jpn J Clin Oncol. 1997 Apr;27(2):95-100 [9152798.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):743-7 [12753162.001]
  • [Cites] Acta Oncol. 1997;36(1):78-80 [9090972.001]
  • [Cites] Fukuoka Igaku Zasshi. 1976 Feb;67(2):65-73 [177344.001]
  • [Cites] Int J Clin Oncol. 2002 Apr;7(2):128-32 [12018111.001]
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):156-60 [9058136.001]
  • [Cites] Am J Gastroenterol. 1991 Sep;86(9):1167-75 [1715667.001]
  • [Cites] Gan To Kagaku Ryoho. 1999 Jan;26(1):149-52 [9987513.001]
  • [Cites] Hum Pathol. 1984 May;15(5):460-8 [6327495.001]
  • [Cites] Cancer. 1985 Dec 15;56(12 ):2771-8 [2996747.001]
  • (PMID = 16378235.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


24. El-Rayes BF, Ibrahim D, Shields AF, LoRusso PM, Zalupski MM, Philip PA: Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. Invest New Drugs; 2005 Jan;23(1):57-62
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
  • PATIENTS AND METHODS: Eligibility criteria included: a diagnosis of non-hematologic cancer with no conventional effective therapy, normal renal, liver and bone marrow function, and ECOG performance status of 0-2.
  • Both drugs were administered intravenously on day 1 of a 21-day cycle.
  • Three patients with adenocarcinoma of the stomach, fibrosarcoma of the stomach and renal cell carcinoma showed objective antitumor responses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Drug Carriers. Female. Humans. Injections, Intravenous. Liposomes. Male. Maximum Tolerated Dose. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1979 Nov;91(5):710-7 [496103.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3185-91 [9336354.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1444-54 [11230490.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] J Clin Pharmacol. 1996 Jan;36(1):55-63 [8932544.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 12):32-40 [11552228.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):134-7 [9935243.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1777-85 [7602367.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):801-5 [8471439.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):711-6 [9739435.001]
  • (PMID = 15528981.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


25. Qing C, Jiang C, Zhang JS, Ding J: Induction of apoptosis in human leukemia K-562 and gastric carcinoma SGC-7901 cells by salvicine, a novel anticancer compound. Anticancer Drugs; 2001 Jan;12(1):51-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis in human leukemia K-562 and gastric carcinoma SGC-7901 cells by salvicine, a novel anticancer compound.
  • Salvicine (a novel diterpenoid quinone compound) exhibited a marked antitumor activity on human solid tumor cell lines and BALB/c-nu human carcinoma xenografts in our earlier studies, and it has been chosen as a candidate anticarcinogenic compound in the preclinical research stage.
  • Our results show that salvicine is capable of inhibiting cell proliferation and inducing characteristic changes of apoptosis in both human leukemia K-562 and gastric carcinoma SGC-7901 cells.
  • These effects are dose and time dependent.
  • Meanwhile, this study also shows that the activity of salvicine against K-562 and SGC-7901 cells is similar with regards to both growth inhibition and apoptosis induction, further indicating that salvicine causes these particular effects on solid tumor cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Naphthoquinones / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Cell Division / drug effects. DNA Fragmentation. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11272286.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Naphthoquinones; 0 / salvicine
  •  go-up   go-down


26. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol; 2001 Apr 01;19(7):1985-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.
  • Five patients (33%) developed venous thromboses at the central catheter tip.
  • CONCLUSION: Flavopiridol administered as a single agent for 72 hours every 14 days is inactive in the treatment of gastric cancer.
  • The drug also induced an unexpected higher incidence of vascular thrombosis and fatigue than was anticipated from the phase I trials.
  • Future development of flavopiridol will depend on other doses and schedules in combination with chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Cyclin-Dependent Kinases / antagonists & inhibitors. Flavonoids / therapeutic use. Piperidines / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11283131.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA-69913
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Flavonoids; 0 / Piperidines; 45AD6X575G / alvocidib; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


27. He Y, Jiang Y, Li YJ, Liu XH, Zhang L, Liu LJ, Shi H, Li HN, Ma YC, Jin XM: 19-peptide, a fragment of tumstatin, inhibits the growth of poorly differentiated gastric carcinoma cells in vitro and in vivo. J Gastroenterol Hepatol; 2010 May;25(5):935-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 19-peptide, a fragment of tumstatin, inhibits the growth of poorly differentiated gastric carcinoma cells in vitro and in vivo.
  • SGC7901 gastric carcinoma cells and human umbilical-vein endothelial cells (HUVECs) were exposed to 19-peptide in vitro, and their viability was evaluated by biochemical and histopathological analysis.
  • In vivo, pieces of solid tumor derived from SGC7901 cells were inoculated into the gastric serosa of 36 nude mice, with a biological glue to hold them in place.
  • PTEN was increased in the treatment group and phospho-Akt (pAkt) was decreased in the control group.
  • CONCLUSIONS: These results suggest that 19-peptide inhibits the growth and metastases of poorly differentiated gastric carcinoma cells, primarily by inducing apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Autoantigens / pharmacology. Carcinoma / drug therapy. Cell Differentiation. Cell Proliferation / drug effects. Collagen Type IV / pharmacology. Peptide Fragments / pharmacology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Cell Movement / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Endothelial Cells / drug effects. Endothelial Cells / pathology. Female. Humans. In Situ Nick-End Labeling. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. PTEN Phosphohydrolase / metabolism. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Time Factors. Tumor Burden / drug effects. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546447.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Autoantigens; 0 / Collagen Type IV; 0 / Peptide Fragments; 0 / type IV collagen alpha3 chain; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


28. Ji SR, Zhang Y, Gu QL, Liu BY, Zhu ZG, Lin YZ: [In situ gene therapy for murine gastric carcinoma with UPRT/5-FU enzyme/prodrug system mediated by retrovirus]. Ai Zheng; 2002 Aug;21(8):838-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [In situ gene therapy for murine gastric carcinoma with UPRT/5-FU enzyme/prodrug system mediated by retrovirus].
  • BACKGROUND & OBJECTIVE: 5-Fluorouracil(5-FU), a widely used chemotherapeutic drug, has a limited overall effect in the treatment of human solid tumors due to resistance.
  • In situ gene therapy was performed by regional repeated injections of concentrated and purified recombinant retrovirus carrying UPRT gene intratumorally and followed by administration of 5-FU intraperitoneally(i.p.).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Genetic Therapy / methods. Pentosyltransferases / genetics. Stomach Neoplasms / therapy
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Division / genetics. DNA, Neoplasm / genetics. Female. Gene Expression Regulation, Enzymologic. Genetic Vectors / genetics. Mice. Polymerase Chain Reaction. Prodrugs / therapeutic use. Retroviridae / genetics. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12478888.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 0 / Prodrugs; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.9 / uracil phosphoribosyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Park SR, Choi IJ, Kim CG, Kim YW, Ryu KW, Lee JH, Lee JS, Bae JM, Kim HK: Use of a combination of computed tomography and endoscopy to assess the response to 5-fluorouracil/cisplatin and predict survival in gastric cancer. J Gastroenterol; 2006 Apr;41(4):339-46
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a combination of computed tomography and endoscopy to assess the response to 5-fluorouracil/cisplatin and predict survival in gastric cancer.
  • BACKGROUND: Response of metastatic sites on computed tomography (CT) has been used to assess response in metastatic gastric carcinoma (MGC); however, the role of endoscopy to evaluate the response of the primary gastric lesion is unclear.
  • METHODS: MGC patients naïve to chemotherapy were treated with 5-FU (1000 mg/m(2), days 1-5) and cisplatin (60 mg/m(2), day 1) (FP) every 21 days.
  • Response was assessed by CT [World Health Organization (WHO) criteria/Response Evaluation Criteria In Solid Tumors (RECIST)] every three cycles and/or endoscopy after the third cycle.
  • The combination of CT and endoscopy defined patients into four groups with distinct prognoses according to chemotherapy response: responders on both tests, responders on CT alone, responders on endoscopy alone, and nonresponders on both tests (hazard ratio, 1.00 versus 2.87 versus 5.35 versus 12.3; P < 0.0001).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Endoscopy, Gastrointestinal. Fluorouracil / therapeutic use. Immunosuppressive Agents / therapeutic use. Stomach Neoplasms. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2000 Nov;73(875):1178-84 [11144795.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):56-61 [11516851.001]
  • [Cites] Breast Cancer. 2002;9(2):153-9 [12016395.001]
  • [Cites] Gastric Cancer. 2001;4(1):1-8 [11706621.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2016-23 [6751515.001]
  • [Cites] Gastric Cancer. 2000 Dec 27;3(3):128-133 [11984725.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Jpn J Clin Oncol. 1993 Feb;23(1):41-5 [8459640.001]
  • [Cites] Br J Radiol. 2002 Nov;75(899):903-8 [12466256.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):14-19 [11957065.001]
  • (PMID = 16741613.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Pandita D, Ahuja A, Velpandian T, Lather V, Dutta T, Khar RK: Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. Pharmazie; 2009 May;64(5):301-10
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study investigates the design and characterization of solid lipid nanoparticles (SLNs) containing paclitaxel fabricated by a modified solvent injection technique using stearic acid as lipid and stabilized by a mixture of surfactants, for future evaluation of this colloidal carrier system for the oral delivery of paclitaxel, devoid of the side effects of Cremophor EL.
  • SLN formulations of paclitaxel stabilized by mixture of surfactants i.e. lecithin/poloxamer 188 were developed with smaller size and narrow size distribution.
  • In vitro cytotoxicity assay confirmed that paclitxel entrapped in SLNs showed higher cytotoxicity against cultured hepatocelluler carcinoma cells than paclitaxel alone.
  • The modified solvent injection technique used in this research proved to be a simple, easily available and effective method to produce SLNs and could be used for controlled delivery of different lipophilic drugs for cancer chemotherapy.
  • [MeSH-minor] Cell Line, Tumor. Chemistry, Pharmaceutical. Delayed-Action Preparations. Drug Compounding. Electrochemistry. Excipients. Freeze Drying. Humans. Kinetics. Lipids / chemistry. Microscopy, Electron, Transmission. Nanoparticles. Particle Size. Poloxamer. Solvents. Spectroscopy, Fourier Transform Infrared. Stomach / chemistry. X-Ray Diffraction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530440.001).
  • [ISSN] 0031-7144
  • [Journal-full-title] Die Pharmazie
  • [ISO-abbreviation] Pharmazie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Delayed-Action Preparations; 0 / Excipients; 0 / Lipids; 0 / Solvents; 106392-12-5 / Poloxamer; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


31. Davids PH, Bartelsman JF, Tilanus HW, van Lanschot JJ: [Consequences of caustic damage of the esophagus]. Ned Tijdschr Geneeskd; 2001 Nov 3;145(44):2105-8
Hazardous Substances Data Bank. ACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following ingestion of a highly concentrated acetic acid solution, three women aged 29, 23 and 25 years old, suffered damage to the oesophagus and the stomach, respiratory and renal insufficiency and haemolysis.
  • After intensive treatment, gastric tube reconstruction was carried out in 2 of these patients, and the third woman required repeated dilatations of the oesophageal stricture from 6 weeks after ingestion onwards.
  • This resulted in a normal passage of solid food in all women.
  • A squamous cell carcinoma was diagnosed and treated with chemotherapy, oesophagus-cardia resection and gastric tube reconstruction.
  • Subsequent treatment can vary from endoscopic dilations to gastric tube reconstruction following resection of the oesophagus.
  • [MeSH-minor] Acetic Acid / adverse effects. Adult. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / surgery. Deglutition Disorders / etiology. Dilatation / methods. Esophageal Neoplasms / etiology. Esophageal Neoplasms / surgery. Esophagus / pathology. Esophagus / surgery. Female. Humans. Male. Middle Aged. Secondary Prevention. Sodium Hydroxide / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • Hazardous Substances Data Bank. SODIUM HYDROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11723750.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 55X04QC32I / Sodium Hydroxide; Q40Q9N063P / Acetic Acid
  • [Number-of-references] 9
  •  go-up   go-down


32. Zhang D, Holmes WF, Wu S, Soprano DR, Soprano KJ: Retinoids and ovarian cancer. J Cell Physiol; 2000 Oct;185(1):1-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer is the seventh most common cancer in women worldwide, after breast, cervix, colon/rectum, stomach, corpus uteri, and lung cancers.
  • In the U.S., ovarian cancer is the second most common gynecologic cancer, and is the fourth leading cause of solid tumor cancer deaths among women.
  • Currently, postoperative chemotherapy of ovarian cancer is still suboptimal.
  • Drug resistance is a common problem resulting in only 20 approximately 30% overall 5-year survival rates.
  • Clearly, continued development of alternative therapeutic strategies is essential for the management of this fatal disease.
  • This review will initially summarize what is known about the pathological and molecular characteristics of ovarian carcinoma.
  • Following this general review of retinoids and their function, data supporting the role of retinoic acid as a suppresser of ovarian carcinoma cell growth will be presented.
  • Particular attention will be paid to studies suggesting that members of the RB family of proteins and RB2/p130, in particular, are the molecular targets responsible for retinoid mediated inhibition of ovarian carcinoma cell growth.
  • It will be clear from the studies summarized in this review that retinoids represent a potentially powerful alternative to present chemotherapeutic approaches to the treatment of late stage ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Fenretinide / pharmacology. Fenretinide / therapeutic use. Ovarian Neoplasms / drug therapy. Retinoids / pharmacology. Retinoids / therapeutic use
  • [MeSH-minor] Cell Differentiation / drug effects. Cell Division / drug effects. Female. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10942515.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI07101; United States / NCI NIH HHS / CA / CA64945; United States / NIDDK NIH HHS / DK / DK49045
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CD 437; 0 / Retinoids; 187EJ7QEXL / Fenretinide
  • [Number-of-references] 150
  •  go-up   go-down


33. Gubanski M, Johnsson A, Fernebro E, Kadar L, Karlberg I, Flygare P, Berglund A, Glimelius B, Lind PA, Gastric Cancer Taxotere vs. Campto Trial (GATAC) Study Group: Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer; 2010 Aug;13(3):155-61
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The optimal chemotherapy in patients with advanced gastric carcinoma (GC) is yet to be determined.
  • METHODS: Patients with previously untreated locally advanced or metastatic GC and with measurable lesions (response evaluation criteria in solid tumors; RECIST) were randomly assigned to start with docetaxel 45 mg/m(2) (arm T) or irinotecan 180 mg/m(2) (arm C) with bolus/44-h infusion of 5-Fu/Lv (day 1 every 2 weeks).
  • RESULTS: Eighty-one patients were randomized and 78 started treatment.
  • CONCLUSION: This is the first randomized comparison of two of the newer cytostatic drugs in GC therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leucovorin / therapeutic use. Stomach Neoplasms / drug therapy. Vitamin B Complex / therapeutic use
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Statistics as Topic. Surveys and Questionnaires. Survival Analysis. Taxoids / administration & dosage. Time Factors

  • MedlinePlus Health Information. consumer health - B Vitamins.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii41-4 [12810457.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Gastric Cancer. 2002;5(3):142-7 [12378340.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1450-7 [18558665.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):380-3 [7914428.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):301-6 [10811496.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):47-51 [11249048.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004064 [15846694.001]
  • [Cites] Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33 [526911.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):341-4 [10955859.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):641-6 [11857295.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3205-9 [17664467.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):204-13 [16482619.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92 (12 ):2122-8 [15942629.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 May;47(5):380-4 [11391851.001]
  • [Cites] Med Oncol. 2007;24(2):137-46 [17848736.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Med Oncol. 1996 Jun;13(2):87-93 [9013471.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1773-81 [15550582.001]
  • (PMID = 20820984.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0H43101T0J / irinotecan; 12001-76-2 / Vitamin B Complex; 15H5577CQD / docetaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Investigator] Glimelius B; Lind P; Gunven P; Bandmann U; Nygren P; Pedersen D; Hansen J
  •  go-up   go-down


34. Sato Y, Kashimoto S, MacDonald JR, Nakano K: In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours. Eur J Cancer; 2001 Jul;37(11):1419-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, the in vivo antitumour efficacy of MGI-114 was examined in a panel of human tumour xenograft models consisting mainly of human lung and gastric tumours, and compared with that of other antitumour drugs such as irinotecan, paclitaxel, cisplatin, doxorubicin, vindesine, etoposide and 5-fluorouracil (5-FU).
  • In human tumour xenograft models of nasopharyngeal, breast and colon carcinoma and melanoma, MGI-114 exerted a strong antitumour activity with complete tumour regression being observed.
  • The antitumour efficacy of MGI-114 was generally higher than or equivalent to that of other antitumour drugs such as irinotecan and paclitaxel.
  • These results support the potential utility of MGI-114 in the treatment of a variety of human solid tumours.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Lung Neoplasms / drug therapy. Sesquiterpenes / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Animals. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Small Cell / drug therapy. Colonic Neoplasms / drug therapy. Humans. Melanoma / drug therapy. Mice. Mice, Nude. Xenograft Model Antitumor Assays / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11435075.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Sesquiterpenes; 6B799IH05A / irofulven
  •  go-up   go-down


35. Ohkoshi M, Okuda S: Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403. Anticancer Res; 2002 Mar-Apr;22(2A):821-3
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, oral administration of ONO-3403 was used to challenge 3-methylcholanthrene-induced carcinoma.
  • This drug was administered 3 times daily for 9 weeks via a stomach tube at a dose of 10 mg/kg in a 1-ml volume in 6 mice harboring solid tumors.
  • This protease inhibitor significantly inhibited tumor growth (p<0.001) and prolonged survival-time (p<0.01).
  • [MeSH-major] Allylglycine / analogs & derivatives. Allylglycine / pharmacology. Benzamidines / pharmacology. Carcinoma, Squamous Cell / drug therapy. Serine Proteinase Inhibitors / pharmacology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Animals. Body Weight / drug effects. Cell Division / drug effects. Female. Growth Inhibitors / pharmacology. Mice

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12014657.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Benzamidines; 0 / Growth Inhibitors; 0 / Serine Proteinase Inhibitors; 0 / ethyl N-allyl-N-(2-methyl-3-(4-(4-amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate; 1069-48-3 / Allylglycine
  •  go-up   go-down


36. Shen L, Wang JS, Shen HJ, Song YC, Tan RX: A new cytotoxic trichothecene macrolide from the endophyte Myrothecium roridum. Planta Med; 2010 Jul;76(10):1004-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new cytotoxic roridin-type trichothecene macrolide named roritoxin E(1) was characterized from the solid culture of Myrothecium roridum IFB-E091 (residing originally inside Artemisia annua root), together with the known compounds lumichrome (2), (22 E,24 S)-cerevisterol (3), and (22 E,24 R)-6 beta-methoxy-ergosta-7,22-diene-3 beta,5 alpha-diol (4).
  • Compound 1 was demonstrated to be inhibitory in vitro against the gastric carcinoma SGC-7901 and hepatocarcinoma SMMC-7721 cell lines, with IC (50) values of 0.26 and 10.54 microg/mL, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biological Products / therapeutic use. Carcinoma / drug therapy. Hypocreales / chemistry. Liver Neoplasms / drug therapy. Macrolides / therapeutic use. Stomach Neoplasms / drug therapy. Trichothecenes / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 20195960.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biological Products; 0 / Macrolides; 0 / Trichothecenes; 0 / roritoxin E
  •  go-up   go-down


37. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K, Tsutsumi Y: Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep; 2005 Nov;14(5):1223-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
  • Fluoropyrimidines [5-Fluorouracil (5-FU) and its prodrugs] have been widely used in the treatment of solid cancers.
  • The anticancer effects primarily depend on intratumoral levels of enzymes metabolizing the drugs, such as dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), thymidine phosphorylase (TP), and thymidylate synthase (TS).
  • In order to know the tumor types susceptible to respective fluoropyrimidines, we investigated the expression of DPD, OPRT, TP and TS in various types of cancer with the immunoperoxidase method.
  • These four enzymes existed in all of the cancer types studied, such as pulmonary, gastric, colorectal, hepatic, cholecystic, pancreatic, renal, urocystic, and mammary cancers.
  • Respective types of cancers presented characteristic immunohistochemical features as follows: pulmonary adenocarcinoma, DPD- and TP-high; pulmonary squamous cell carcinoma, TS- and TP-high; intestinal-type gastric adenocarcinoma, TP-high; diffuse-type gastric adenocarcinoma, DPD-low and TS-high; colorectal adenocarcinoma, DPD- and TP-low, hepatocellular carcinoma, DPD-high, and TS- and OPRT-low; cholecystic adenocarcinoma, DPD- and TS-high; renal cell carcinoma, DPD-low, and OPRT- and TP-high; urocystic transitional cell carcinoma, DPD-high and OPRT-low; and mammary ductal carcinoma, OPRT-low, and TS- and TP-high.
  • The enzyme expression pattern in cancer tissue was generally similar to that of their normal counterparts.
  • However, TP immunoreactivity in adenocarcinomas of the lung, stomach and gallbladder, and urothelial carcinoma of the urinary bladder was stronger, and DPD immunoreactivity in adenocarcinoma of the breast was weaker, when compared with normal epithelial cells.
  • Fluoropyrimidine treatment may be selected, based on the simultaneous immunohistochemical evaluation of the fluoropyrimidine metabolic enzymes.
  • [MeSH-major] Antimetabolites, Antineoplastic / metabolism. Antimetabolites, Antineoplastic / pharmacology. Fluorouracil / metabolism. Fluorouracil / pharmacology. Neoplasms / drug therapy. Neoplasms / enzymology
  • [MeSH-minor] Dihydrouracil Dehydrogenase (NADP) / metabolism. Drug Resistance. Humans. Immunohistochemistry. Orotate Phosphoribosyltransferase / metabolism. Thymidine Phosphorylase / metabolism. Thymidylate Synthase / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211289.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil
  •  go-up   go-down


38. Kemmner W, Wan K, Rüttinger S, Ebert B, Macdonald R, Klamm U, Moesta KT: Silencing of human ferrochelatase causes abundant protoporphyrin-IX accumulation in colon cancer. FASEB J; 2008 Feb;22(2):500-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, we demonstrated accumulation of the heme precursor protoporphyrin-IX (PpIX) in gastrointestinal tumor tissues.
  • Accordingly, in an in vitro model of several carcinoma cell lines, ferrochelatase down-regulation and loss of enzymatic activity corresponded with an enhanced PpIX-dependent fluorescence.
  • Direct detection of PpIX in minute amounts was achieved by a specifically developed pulsed solid-state laser dual delay fluorimetry setup.
  • Our results show that in malignant tissue a transcriptional down-regulation of FECH occurs, which causes endogenous PpIX accumulation.
  • Furthermore, accumulation of intracellular PpIX because of FECH siRNA silencing provides a small-molecule-based approach to molecular imaging and molecular therapy.
  • [MeSH-minor] Aminolevulinic Acid / pharmacology. Cell Line, Tumor. Gene Expression Regulation, Enzymologic / drug effects. Heme / metabolism. Heme Oxygenase (Decyclizing) / metabolism. Humans. RNA, Messenger / genetics. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875605.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protoporphyrins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 42VZT0U6YR / Heme; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid; EC 1.14.99.3 / Heme Oxygenase (Decyclizing); EC 4.99.1.1 / Ferrochelatase
  •  go-up   go-down


39. Bi S, Liu JR, Li Y, Wang Q, Liu HK, Yan YG, Chen BQ, Sun WG: gamma-Tocotrienol modulates the paracrine secretion of VEGF induced by cobalt(II) chloride via ERK signaling pathway in gastric adenocarcinoma SGC-7901 cell line. Toxicology; 2010 Jul-Aug;274(1-3):27-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypoxia is a common characteristic feature of solid tumors, and carcinoma cells are known to secrete many growth factors.
  • Both basal level and cobalt(II) chloride-induced HIF-1alpha protein accumulation and VEGF paracrine secretion were inhibited in SGC-7901 cells treated with gamma-tocotrienol at 60 micromol/L treatment for 24 h.
  • These data suggest that HIF-1alpha/VEGF could be a promising target for gamma-tocotrienol in an effective method of chemoprevention and chemotherapy in human gastric cancer.
  • [MeSH-major] Proteins / metabolism. Stomach Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adenocarcinoma. Cell Line. Chromans. Cobalt / pharmacology. Guanylate Cyclase. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / pharmacology. Mitogen-Activated Protein Kinase 3 / metabolism. Mitogen-Activated Protein Kinase 3 / pharmacology. Neovascularization, Pathologic. Phosphorylation. Receptors, Cytoplasmic and Nuclear. Signal Transduction / drug effects. Vascular Endothelial Growth Factors / metabolism. Vascular Endothelial Growth Factors / pharmacology. Vitamin E / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. COBALT, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20452389.001).
  • [ISSN] 1879-3185
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Chromans; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Proteins; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 1406-18-4 / Vitamin E; 3G0H8C9362 / Cobalt; 4382-43-8 / plastochromanol 8; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / soluble guanylyl cyclase
  •  go-up   go-down


40. Monaco AP: The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation; 2009 Jan 27;87(2):157-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Posttransplant Kaposi's sarcoma and nonmelanotic skin malignancies (NMSC) frequently undergo remission/regression after conversion to mTORi immunosuppression (IS), especially early, small, and low-grade lesions, whereas larger, aggressive, and metastatic skin tumors are less likely to respond. mTORi-based IS is effective and well tolerated in orthotopic liver transplant patients with hepatocellular carcinoma (HCC) achieving excellent survival and disease-free intervals, particularly with extended criteria tumors, although the evidence that mTORi prevents HCC recurrence after orthotopic liver transplantation is only suggestive.
  • Documentation of regression/remission of other solid-organ dNPTM (colon, stomach, breast, etc.) after mTORi conversion is essentially absent with only anecdotal reports lacking follow-up data.
  • Nevertheless, reduced incidence of all of dNPTMs and remission/regression of the commonest posttransplant tumors with mTOR therapy are strong reasons to expand the use of mTORi.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunosuppressive Agents / therapeutic use. Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / metabolism. Transplantation / adverse effects
  • [MeSH-minor] Animals. Calcineurin Inhibitors. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / etiology. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / etiology. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / etiology. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / enzymology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / etiology. Skin Neoplasms / drug therapy. Skin Neoplasms / etiology. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155967.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 0 / Protein Kinase Inhibitors; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  • [Number-of-references] 95
  •  go-up   go-down


41. Kakeji Y, Maehara Y, Sumiyoshi Y, Oda S, Emi Y: Angiogenesis as a target for gastric cancer. Surgery; 2002 Jan;131(1 Suppl):S48-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The growth of solid tumors and the formation of metastases depend on angiogenesis.
  • In in vivo experiments antiangiogenic agents with cytotoxic anticancer drugs formed a highly effective modulator combination for the treatment of the Lewis lung carcinoma against primary and metastatic disease.
  • CONCLUSIONS: Antiangiogenic agents may thus be valuable for long-term administration to maintain tumor dormancy because drug resistance does not develop, and these agents have a sustained effect.
  • As a target, antiangiogenic therapy may therefore be potentially able to prolong survival time of patients with gastric cancer.
  • [MeSH-major] Neovascularization, Pathologic / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Genetic Therapy. Humans

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11821787.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


42. Wu DD, Xiao YF, Geng Y, Hou J: Antitumor effect and mechanisms of arsenic trioxide on subcutaneously implanted human gastric cancer in nude mice. Cancer Genet Cytogenet; 2010 Apr 15;198(2):90-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The solid tumor model was created in nude mice with the gastric cancer cell line SGC-7901.
  • In nude mice, after treatment with 5 mg/kg and 2.5 mg/kg As(2)O(3), approximately 50% and 30% tumor growth inhibition were observed, respectively (P < 0.05 for both treatment groups).
  • The fluorescence intensity levels of apoptotic cells in tumor were significantly higher in the arsenic-treated groups (P < 0.05 for both treatment groups).
  • The expression of Fas protein increased in dose- and time-dependent manner after the treatment with As(2)O(3), but that of FasL protein showed no significant difference between control and treated groups.
  • [MeSH-major] Arsenicals / pharmacology. Arsenicals / therapeutic use. Carcinoma / drug therapy. Oxides / pharmacology. Oxides / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Cell Proliferation / drug effects. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Subcutaneous Tissue. Transplantation, Heterotopic. Tumor Burden / drug effects. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20362223.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


43. Cserni G, Vágó T, Török N, Gaál Z, Velkei T, Serényi P, Göczo K, Tusa M, Kovács K, Szucs M: [Carcinomatous meningitis]. Lege Artis Med; 2007 Oct;17(10):688-93
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Carcinomatous meningitis is a serious complication of advanced stage solid tumours, which may become more common with improved survival.
  • CASE REPORTS: A 53-year-old woman with a recent history of breast cancer (pT2pN2M0) had been treated by mastectomy and adjuvant chemotherapy and radiotherapy.
  • The rapidly progressive neurological symptoms and the history of breast cancer and findings suggesting pancreatic head tumour, respectively, led to the clinical diagnosis of carcinomatous meningitis in both cases, despite any evidence on CT scans or a negative MR scan, though of limited value, in the first case.
  • This diagnosis was confirmed by the laboratory and cytological findings of the cerebrospinal fluid, and also by the post mortem examination, since both patients died within a month after the onset of the symptoms.
  • The primary tumour in the second patient proved to be a widely metastasizing diffuse type gastric cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / complications. Meningeal Carcinomatosis / etiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Ductal, Breast / complications. Diagnosis. Diplopia / etiology. Fatal Outcome. Female. Headache / etiology. Humans. Hypertension / complications. Lymphatic Metastasis. Male. Middle Aged. Muscle Weakness / etiology. Vertigo / etiology. Vomiting / etiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227599.001).
  • [ISSN] 0866-4811
  • [Journal-full-title] Lege artis medicinae : új magyar orvosi hírmondó
  • [ISO-abbreviation] Lege Artis Med
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


44. Wang KR, Zhang BZ, Zhang W, Yan JX, Li X, Wang R: Potent antitumor effects of a novel actinomycin D analog Leu5AMD. Cancer Lett; 2008 Sep 8;268(1):38-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, an attempt has been made to investigate the effects of Leu5AMD on the proliferation of human gastric carcinoma cell line SGC-7901.
  • After treatment with Leu5AMD, the loss of mitochondrial potential and the decrease of bcl-2 gene expression were observed in apoptotic cells, suggesting that Leu5AMD may be involved in mitochondria and bcl-2 related apoptotic pathway.
  • Treatment with Leu5AMD markedly suppressed the growth of Sarcoma xenograft.
  • These results suggest that Leu5AMD may be used as a promising chemotherapeutical agent for patients affected by gastric carcinoma and other solid cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Dactinomycin / analogs & derivatives. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans. Membrane Potential, Mitochondrial / drug effects. Mice. Proto-Oncogene Proteins c-bcl-2 / metabolism. Sarcoma 180 / drug therapy. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18448241.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / actinomycin D, valyl(2,2')-N-methylleucyl(5,5')-; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


45. Král V, Hajdúch M, Neoral C, Klein J, Mihál V, Orel M, Aujeský R, Vyslouzil K, Cwiertka K, Kolek V, Nosková V: [Significance and possibilities of cytostatic treatment of malignant tumors: testing the effects of cytostatics]. Rozhl Chir; 2000 Mar;79(3):134-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance and possibilities of cytostatic treatment of malignant tumors: testing the effects of cytostatics].
  • Four groups of tumours were examined by the MTT test: breast cancer, carcinoma of the colon and rectum, of the lungs and oesophagus + stomach.
  • The results of the MTT test were not used so far in the therapeutic protocol in all patients where the examination was made, as in solid tumours, contrary to haemo-blastomas, usually common empirically tested protocols are used.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Screening Assays, Antitumor
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Cell Survival / drug effects. Female. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / pathology. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10838948.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] CZECH REPUBLIC
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


46. Changlong L, Hezhen W, Yongping H, Yanfang Y, Yanwen L, Jianwen L: 6-O-Angeloylenolin induces apoptosis through a mitochondrial/caspase and NF-kappaB pathway in human leukemia HL60 cells. Biomed Pharmacother; 2008 Jul-Aug;62(6):401-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 6-O-Angeloylenolin, a sesquiterpene lactone from Centipeda minima, has been known to have anti-tumor activity against human colorectum, liver, stomach, lung, and skin tumor cells.
  • Furthermore, we confirmed that 6-O-angeloylenolin could obviously inhibit the solid cancer growth in Lewis lung cancer xenograft models.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Lactones / pharmacology. Leukemia, Promyelocytic, Acute / drug therapy. Sesquiterpenes / pharmacology
  • [MeSH-minor] Animals. Asteraceae / chemistry. Carcinoma, Lewis Lung / drug therapy. Caspase 3 / drug effects. Caspase 3 / metabolism. Caspase 7 / drug effects. Caspase 7 / metabolism. Gene Expression Regulation, Neoplastic / drug effects. HL-60 Cells. Humans. Male. Membrane Potentials / drug effects. Mice. Mice, Inbred C57BL. Mitochondria / drug effects. Mitochondria / metabolism. NF-kappa B / drug effects. NF-kappa B / metabolism. Reactive Oxygen Species / metabolism. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077129.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / 6-O-angeloylenolin; 0 / Antineoplastic Agents, Phytogenic; 0 / Lactones; 0 / NF-kappa B; 0 / Reactive Oxygen Species; 0 / Sesquiterpenes; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  •  go-up   go-down


47. Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK: Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res; 2004 Aug 1;10(15):4913-21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The oral fluoropyrimidine S-1, which consists of a mixture of a 5-fluorouracil (5-FU) prodrug (tegafur), a dihydropyrimidine dehydrogenase inhibitor [5-chloro-2,4-dihydroxypyrimidine (CDHP)], and an inhibitor of orotate phosphoribosyltransferase [potassium oxonate (oxonic acid)], was developed to increase the feasibility and therapeutic index of 5-FU administered orally.
  • EXPERIMENTAL DESIGN: Patients with advanced solid malignancies were treated with escalating doses of S-1 on a once-daily oral schedule for 28 days every 5 weeks.
  • A partial response and a 49% reduction in tumor size were observed in patients with fluoropyrimidine- and irinotecan-resistant colorectal carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Oxonic Acid / administration & dosage. Oxonic Acid / pharmacokinetics. Pyridines / administration & dosage. Pyridines / pharmacokinetics. Pyrimidines / administration & dosage. Pyrimidines / pharmacokinetics. Tegafur / administration & dosage. Tegafur / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / pharmacokinetics. Antineoplastic Agents / pharmacology. Area Under Curve. Dose-Response Relationship, Drug. Drug Combinations. Enzyme Inhibitors / pharmacology. Female. Follow-Up Studies. Humans. Lung Neoplasms / drug therapy. Male. Maximum Tolerated Dose. Middle Aged. Orotate Phosphoribosyltransferase / antagonists & inhibitors. Stomach Neoplasms / drug therapy. Time Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297391.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-chlorodihydroxypyridine; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / Pyridines; 0 / Pyrimidines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 675-21-8 / 5-fluoropyrimidine; EC 2.4.2.10 / Orotate Phosphoribosyltransferase
  •  go-up   go-down


48. Mansueto G, Longo F: [Toward the cure of "early-stage" solid tumors: the role of docetaxel]. Tumori; 2005 Jul-Aug;91(4):suppl 17-28
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Toward the cure of "early-stage" solid tumors: the role of docetaxel].
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Neoplasms / drug therapy. Neoplasms / pathology. Taxoids / therapeutic use
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / secondary. Clinical Trials as Topic. Congresses as Topic. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Neoplasm Staging. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277113.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  • [Number-of-references] 32
  •  go-up   go-down






Advertisement